CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
Prasugreldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01178099
NCT01178099Phase 1Completed
CompareCT.gov

A Pharmacokinetic and Pharmacodynamic Assessment of Prasugrel in Healthy Adults and Adults With Sickle Cell Disease

Eli Lilly and Company·interventional·Posted Aug 9, 2010·Updated Feb 15, 2012

In Brief

A Phase 1 clinical trial evaluating Prasugrel for Anemia, Sickle Cell. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The purpose of this study is to measure the exposure to prasugrel's active metabolite and the pharmacodynamic effects of prasugrel treatment in people with Sickle Cell Disease (SCD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Sickle Cell
CountriesUnited Kingdom
CollaboratorsDaiichi Sankyo Co., Ltd.

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 9, 2010
Enrollment StartJul 1, 2010
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.9 years ago

Interventions

Prasugreldrug

Oral, daily for 12 days